Experimental models of cardiac transplantation: design determines relevance
- PMID: 25160697
- PMCID: PMC4321684
- DOI: 10.1097/MOT.0000000000000113
Experimental models of cardiac transplantation: design determines relevance
Abstract
Purpose of review: Experimental models have contributed enormously to basic immunology. However, the use of reductionist experiments has produced results that are not always successfully translated into the clinic. Recently, incorporation of more realistic clinical parameters in experimental designs has produced new insights relevant to cardiac transplantation.
Recent findings: Experiments in mice have provided crucial insights into the concept that T cell responses to pathogens generate memory cells with cross-reactive specificities for histocompatibility antigens. These memory T cells are resistant to current immunosuppressive strategies. Memory T cells infiltrate grafts within hours after transplantation, and grafts subjected to clinically relevant periods of cold ischemia are more susceptible to injury by this cellular infiltrate. Early immune responses now can be investigated with improved 'humanized' mice. Mice with multiple knock-in genes for human cytokines support development of human monocytes, macrophages and natural killer cells in increased numbers and with better function.
Summary: Better and more clinically relevant experimental designs are providing animal models tailored to address clinic exigencies.
Conflict of interest statement
The authors have no conflict of interest with the information presented in this review.
References
-
- Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents and actions. 1976;6(4):468–475. - PubMed
-
- Calne RY, White DJ, Rolles K, et al. Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet. 1978;1(8075):1183–1185. - PubMed
-
- Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3):443–453. - PubMed
-
- Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature biotechnology. 2007;25(11):1256–1264. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
